Abstract Hereditary breast cancer syndrome was firstly associated with BRCA1 and BRCA2 genes the mutations of which confer high risk to develop breast and/or ovarian cancer. Double heterozygosity is a rare condition in which both BRCA1 and BRCA2 mutations are present in a family at the same time. In the current study, a family with double heterozygosity has been reported. Furthermore, for the first time a molecular analysis in both proband lineages, maternal and paternal, has been reported to understand the provenience of both germinal mutations.The case regards a woman who developed breast and ovarian cancer with liver metastasis which presented two mutations, each in the two genes, transmitted from her mother and her father, respectively. In this family all available members have been investigated. The concomitant presence of these peculiar mutations was never reported before suggesting a link with Caucasian population from Southern Italy.
Introduction
High-penetrating BRCA1 and BRCA2 genes germline mutations have been associated with hereditary breast cancer risk. Women with germline BRCA mutations have a relevant risk increase for breast and ovarian cancer if compared with the global population. It has been estimated that about 10-15% of cancer patients have mutations in BRCA1 and 7% in BRCA2 genes [1] . There are different types of mutations listed in Breast Cancer Information Core professional databases (BIC). Most are small insertions or deletions generating truncated proteins missing common functionalities. Moreover, missense mutations, intronic variants sequences (IVS) and unclassified variants (UV) have been identified, reporting an unclear role in breast cancer susceptibility [2] . Previous studies have highlighted that 80% of patients with a cancer family history and a high BRCA mutation risk have at least one polymorphism that could increase breast cancer risk [1, 3] . Furthermore, screening the mutations in the two genes and approaching with new technical methods, large genomic rearrangements have been identified. In particular, at least 81 different large genomic rearrangements (LGRs) in BRCA1 gene and few rearrangements in BRCA2 gene have been characterized [4] .
However, the probability of having both genes mutated in the same individual is very low and only few cases showing double heterozygosity (DH) in Italian population have been described [5] [6] [7] .
In the current study, one case of breast cancer affected family with an individual with DH for BRCA1 and BRCA2 genes mutations has been reported. [8] . The patient, who was a smoker (5 cigaretts/day), was also characterized according to pathological features [9] .
DNA was extracted using QIAmp DNA blood midi kit (Qiagen, Valencia, CA, USA) following manufacturer's instructions. Molecular analysis was performed as previously described [1, 2, 8] . Family's information has allowed to design a pedigree with the Progeny v6 Program.
The variants in the sequence were characterized and compared to those present in the online database BIC [http://www.research.nhgri.nih.gov/bic/].
Case report
This is a case of a 44-year-old female proband who was enrolled in the Genetic Counseling Program of NCC Bari during 2008. In 2004, the patient had undergone a nodulectomy on the left side and in 2005 a quadrantectomy. Histopathological analysis showed a medium grade intraductal carcinoma with negative ER, PgR and HER-2. Subsequently, she underwent a local radiotherapy. In 2008, she was affected by a third grade bilateral papillary ovarian adenocarcinoma. On analyzing the peritoneal washing liquid, ER and PgR values were negative. In 2010, metastases of ovarian origin have been diagnosed in the liver. Molecular analysis showed a double heterozygosity for BRCA1 and BRCA2 genes: the BRCA1 NT_5382insC and the BRCA2 NT_6024delTA mutations. During the counseling interview, the patient referred a maternal history of breast and ovarian cancer. Her mother developed breast and ovarian cancer at 58 and 60 years, respectively. For this family, the proband's mother, father, one unaffected sister and two unaffected brothers were available for genetic analysis. Both mutations resulted to be inherited, one from the mother (BRCA1 NT_5382insC) and one from the father (BRCA2 NT_6024delTA). With exception of the proband, who had a DH for BRCA1 and BRCA2 gene mutations, only the unaffected proband's sister presented BRCA2 NT_6024delTA mutation. Figure 1 shows the genealogic tree of this family.
Discussion
In the current study, one case of DH (BRCA1 NT_5382insC and BRCA2 NT_6024delTA) in a patient belonging to a family with breast and ovarian cancer history has been reported. Interestingly, analyzing both maternal and paternal lineages we evidenced that the two germinal mutations were, respectively, inherited: one from the mother and one from the father. The double heterozygosity is the presence of pathological mutations both in BRCA1 and in BRCA2 genes in the same subject and it is an extremely rare event mostly shown in Ashkenazi Jewish [10] . The BRCA1 NT_5382insC is the most common mutation in Caucasian population from Puglia [1] and in Askenazi which accounted for 26 (10.1%) of all the BRCA1 founder mutations, appearing in 60% of ovarian cancer and 30% of breast cancer in Ashkenazi population [11] . The BRCA1 NT_5382insC mutation is located near the 3 0 -end of the BRCA1 coding region and consists of an insertion of the nucleotide deoxycytidylate (C) at nucleotide position 5382 of the gene. Analyzing a possible correlation between this BRCA1 mutation and specific phenotypes, Rennert et al. [12] showed that the BRCA1 NT_5382insC mutation was more expressed in bilateral breast cancer (38.9% of families, 15.4% of women with cancer, 6.1% of all women in family) and metachronous breast and ovary tumors (22.2, 9.8 and 4.5% correspondingly). Moreover, studies about ovarian cancer's lifetime risk and inherited BRCA1 NT_5382insC mutation in family members and in population series reported a lifetime risk rate of 28-66% [13] .
The second alteration found in this studied proband was BRCA2 NT_6024delTA mutation (Accession Number BIC Fig. 1 Pedigree of family #212. Proband is indicated by arrow. Grey/black colored circles represent affected women. Slash indicates that the subject is deceased. Numbers below the symbols are the ages at the diagnoses. B1 and B2 are BRCA1 and BRCA2, respectively; wt is normal gene otherwise mutation is reported. BrCA breast cancer, OvCa ovarian cancer database: 4752). This mutation consists of a deletion of the nucleotides TA that generates the truncation of the BRCA2 protein at codon 1943 [14] . It was firstly identified in Italian Breast and/or Ovarian Carcinoma patients in 1998 [15] , but subsequently it has been detected in the ovarian cancer cluster region (OCCR) of Greek patients [16] , and in other different population with breast cancer [1] . No published data demonstrated a founder effect of this BRCA2 mutation.
The current study is the first describing these two mutations in DH and it is the first registration of a DH case in Southern Italian population.
Even if rare, most common mutations reported in DH were BRCA1 NT_185delAG and BRCA2 NT_6174delT [17] which presented a typical phenotype [10, 17] . Indeed, BRCA1 NT_5382insC has been reported in DH very few times [10, 18] showing biallelic inactivation of either BRCA1 or BRCA2 thus suggesting that these genetic events are functionally equivalent in initiating tumorigenesis.
By reviewing published data about Ashkenazi Jewish descent, Leegte et al. [10] analyzed 4 cases of double heterozygosity and reviewed 30 cases reported in literature in order to assess phenotypic expression with respect to age of onset, cumulative lifetime risk and multiple primary tumors. The phenotypic expression in this small series of 34 female cases of DH appeared to be highly variable, however, analyzing the cancer incidence in DH at age 70 they reported a value of 80% for breast cancer and 84% for breast and ovarian. Struewing et al. [19] reported a risk of 40-73% at age 70 for BRCA1. Warner et al. [20] calculated a risk of 60% at age 70 for BRCA1, while Satagopan et al. [21] 31-80% at age 70 for BRCA1 and 14-50% for BRCA2. These data were comparable to the family-based data of Brose et al. [22] , with 37% Ashkenazi cases (74-82% by age 70 for BRCA1), and the population-based data (69% for BRCA1 and 74% for BRCA2 at age 70) of King et al. [23] . Only few published data concerned DH incidence in non-Ashkenazi and in Italian population. Claus et al. [24] reported one case of double heterozygosity both in BRCA1 and in BRCA2 genes (BRCA1 W321X and BRCA2 NT_3398del5 mutations) and a woman who had two mutations in BRCA2: BRCA2 S1630X and BRCA2 Q1782K. Regarding the double heterozygosity in Italian population, Cortesi et al. [6] studied an Italian family where two different non-Ashkenazi Jewish mutations were present: 3358T/A in BRCA1 and NT_8756delA in BRCA2. The BRCA1 mutation was inherited since 50% of the members studied were carriers, whereas the BRCA2 NT_8756delA mutation seemed to be a ''de novo'' mutation. Musolino et al. [7] studied a breast cancer patient from Italy with BRCA1 Y1429X and BRCA2 Q2580X mutations reporting the first case in Italy of a non-Ashkenazi double heterozygosity for BRCA1 and BRCA2 genes. At last, Zurardelli et al. [5] discussed four new cases of double heterozygosity showing a non-correlation of age of onset, specific phenotype and a presence of pathological mutations in both genes at the same time. The studied patient also presented a severe phenotype developing breast and ovarian cancer at 38 and 42 years, respectively, both characterized by having absence of hormone receptor and low tumor differentiation grade. Furthermore, she had a bilateral ovarian carcinoma and discovered to have liver metastases of ovarian origin at 44 years. Moreover, the concomitant presence of BRCA1 NT_5382insC and the BRCA2 NT_6024delTA could predispose to a high incidence of ovarian cancer.
In conclusion, our report confirmed one more time the BRCA mutation type dependency on ethnicity. Furthermore, studying BRCA mutations incidence in breast cancer families, in particular when gene mutations are present in DH, has both scientific and clinical relevance. From the scientific point of view it is important to understand the interaction between BRCA1 and BRCA2 which participate in the same metabolic pathway in damage repair. From the clinical point of view, DH patients should undergo a peculiar follow-up and surveillance strategies and, in particular, because most of the DH cases presented in the literature were affected both by breast and ovary cancers, a prophylactic oophorectomy could be suggested.
